The healthcare industry remains awash in paper, and the sector has been slow to recognize the demands on consumers or how much they expect their payment choices to match what they see elsewhere in their lives.
Healthcare was in the spotlight throughout 2016 as the country ramped up to Election Day in November. From the start of the Republican and Democratic primaries, it seemed like each candidate leveraged healthcare as a key campaign focus point. Despite all the political stumping and subsequent headlines, there was still no shift in the trend towards consumerism or any overwhelming sentiment within the industry about the election’s impact. In fact, survey data from LHK Partners shows that when asked about the impact of the 2016 election on healthcare, the response from providers was almost evenly split among positive, neutral and negative.
The data analyzed in the Trends in Healthcare Payments Seventh Annual Report: 2016 reveals that regardless of the political landscape, there are 4 areas that require the industry’s attention:
The Trends in Healthcare Payments Seventh Annual Report: 2016 is now available to download, free of charge. For the last 7 years, InstaMed has released this report to objectively educate the market and promote awareness, change and greater efficiency through quantitative data from the InstaMed Network and qualitative data from healthcare providers, payers and consumers surveyed nationwide.
Next, I will breakdown the trends from the report that explain consumer demands in the industry.
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More